IL1B and neoplasm: On the other hand, the phenomenon in patient #3 suggested that IL6/IL1 blockers were secreted from CART cells in a transient manner only when CART cells were actively killing tumor targets, significantly relieving the concern of compromising patient immunity after CART treatment completed.